A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy.

Jie LiangHuihui ZhangYue HuangLilv FanFanlin LiMin LiYaping YanJunshi ZhangZeyu LiXuanming Yang

Published in: Cancer management and research (2021)

This work provided proof-of-concept evidence for a new strategy to develop a bispecific co-stimulatory activator for treating CLDN18.2+ tumors.

Keyphrases